Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited.
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2018
|
| 在线阅读: | https://doi.org/10.1007/s12325-018-0784-z https://link.springer.com/content/pdf/10.1007/s12325-018-0784-z.pdf |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|